9 May 2022 , 02:42 PM
On a sequential basis, revenues were lower for the quarter by -7.08%. For the full year FY22, the revenues were higher by 30.7% at Rs1,320 crore. Suven Pharma is focused entirely on the high growth contract development and manufacturing operations (CDMO).
The company has declared dividend of Rs.1 per share plus a special dividend of Rs.1 per share. It has taken over 100% of Casper Pharma.
There was a sharp expansion in the EBITDA and the EBITDA margins but there was a sharp spike in the cost of raw materials consumed in the quarter which grew by 49% yoy at Rs1,303 crore. This was partially compensated by inventory efficiency gains.
Net margins stood at 25.19% in Q4FY22 quarter compared to 32.07% in Q4FY21. NPM was lower sequentially against 40.88% in Q3FY22.
Financial highlights for Mar-22 compared yoy and sequentially
Suven Pharma | |||||
Rs in Crore | Mar-22 | Mar-21 | YOY | Dec-21 | QOQ |
Total Income (Rs cr) | ₹ 363.85 | ₹ 259.17 | 40.39% | ₹ 391.59 | -7.08% |
Net Profit (Rs cr) | ₹ 91.67 | ₹ 83.12 | 10.29% | ₹ 160.07 | -42.73% |
Diluted EPS (Rs) | ₹ 3.60 | ₹ 3.27 | ₹ 6.29 | ||
Net Margins | 25.19% | 32.07% | 40.88% |
Related Tags
IIFL Customer Care Number
(Gold/NCD/NBFC/Insurance/NPS)
1860-267-3000 / 7039-050-000
IIFL Securities Support WhatsApp Number
+91 9892691696
www.indiainfoline.com is part of the IIFL Group, a leading financial services player and a diversified NBFC. The site provides comprehensive and real time information on Indian corporates, sectors, financial markets and economy. On the site we feature industry and political leaders, entrepreneurs, and trend setters. The research, personal finance and market tutorial sections are widely followed by students, academia, corporates and investors among others.
Stock Broker SEBI Regn. No: INZ000164132, PMS SEBI Regn. No: INP000002213,IA SEBI Regn. No: INA000000623, SEBI RA Regn. No: INH000000248
This Certificate Demonstrates That IIFL As An Organization Has Defined And Put In Place Best-Practice Information Security Processes.